Join

Compare · FLGC vs NVO

FLGC vs NVO

Side-by-side comparison of Flora Growth Corp. (FLGC) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both FLGC and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $196.10B, about 2088.3x FLGC ($93.9M).
  • Over the past year, FLGC is down 68.8% and NVO is down 43.0% - NVO leads by 25.8 points.
  • NVO has hit the wire 4 times in the past 4 weeks while FLGC has been quiet.
  • NVO has more recent analyst coverage (25 ratings vs 3 for FLGC).
PerformanceFLGC-68.77%NVO-12.28%
2025-06-16+0.00%2026-01-28
MetricFLGCNVO
Company
Flora Growth Corp.
Novo Nordisk A/S
Price
$8.61-24.24%
$43.91+0.06%
Market cap
$93.9M
$196.10B
1M return
+17.46%
-4.14%
1Y return
-68.77%
-43.00%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2021
News (4w)
0
4
Recent ratings
3
25
FLGC

Flora Growth Corp.

Flora Growth Corp., a cannabis company, cultivates, processes, and supplies cannabis products to pharmacies, medical clinics, and cosmetic companies worldwide. It cultivates, processes, and supplies medicinal-grade cannabis oil, and cannabis oil extracts and related products; manufactures and sells skincare and beauty products, such as gel cleanser, eye cream, moisturizer, and hydrating mask; manufactures dermo cosmetic products; and develops and sells pharmaceutical and over-the-counter products, including dietary supplements, phytotherapeutic and nutraceutical products, supplements, and related products. It also manufactures and sells hemp textiles products focuses on servicing the hospitality, medical, and clothing industries on a B2B basis; designs, produces, and supplies juices, chocolate, and chocolate related products to wholesale distributors, pharmacies, supermarkets, and online distributors; and offers and wellness products. The company's brand includes Mambe, Mind Naturals, Almost Virgin, Flora Lab, and Stardog Loungewear. The company was incorporated in 2019 and is headquartered in Toronto, Canada.

NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.